The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd.
To accelerate the development of novel biomarkers, antibody development and vaccine discovery researchers require precision and speed. Even more immediate answers are needed to explore novel treatment opportunities in existing drugs.
Now, more than ever, SCIEX is a committed partner in the race to better understand the mechanisms of this novel virus.
We are closely following direction from various international health organizations and government agencies. SCIEX has a pandemic business continuity plan (“BCP”) in place and our network of external experts, suppliers and partner organizations are providing us with vital, real-time information to help us keep you informed.
Studying viral host protein interactions to ascertain potential therapeutic targets, as well as profiling host immune response to identify potential targets for vaccine development requires in - depth exploration of biomolecules.
From proteins to metabolites to lipids, SCIEX can help you to accelerate the translation of analytical information into biological knowledge.
Listen to Prof. Markus Ralser, Ph.D. from Charité – Universitätsmedizin and Francis Crick Institute discuss his cutting-edge work on clinical classifiers of COVID-19 infection using novel high-throughput proteomics techniques. Listen now
Check out his paper on the same topic
Read about the unique plasma metabolic and lipidomic alterations that were discovered via targeted analysis. Learn how this research has provided valuable knowledge for biomarkers and potential therapeutic targets for COVID-19 from work performed by Xi Zhou and a team of colleagues from State Key Laboratory of Virology, Wuhan Institute of Virology and other institutions. Read paper
Precision and speed have never been more important for vaccine analytics such as attenuated viruses, peptides and proteins, virus-like particles or mRNA and gene-based therapies.
SCIEX technologies combined with new, innovative workflows for the latest generations of mRNA and gene therapy-based vaccines, provide the precision analytics you need to help bring a safe, effective vaccine to market faster.
Discover different types of vaccines and analytical solutions for their development: Learn more
COVID-19 vaccine development via immunopeptidomics to find novel targets: Technical note from PureMHC and SCIEX
OU Health Sciences Center Partners With Pure MHC on COVID-19 Vaccine Project: Read article
There are two main development pipelines. Recombinant antibody development is almost identical to how other monoclonal antibodies are produced. Blood derived anitbody development is isolated and purified from convalescent hosts. Each pathway has many challenges.
SCIEX offers a wide range of LC-MS and CE technologies to help overcome those challenges and bring your therapy to market faster.
Protein therapeutics: Learn more
Streamlined therapeutic peptide map analysis with BPV Flex Software: Read technical note
High throughput data processing and comparison of intact mass analysis using BPV Flex Software 1.0.1: Read technical note
Quantitative LC-MS solution for targeted cell culture media analysis: Read technical note
Quantitative and qualitative analysis of cell culture medium using SWATH® Acquisition: Read technical note
Charge heterogeneity analysis: Learn more
CE-SDS analysis: Learn more
However, the process of rediscovering drugs to identify novel treatment opportunities can be costly and difficult. Speed is of the essence and having the right information at every stage is vital to bring safe and effective therapies to market faster.
SCIEX can help you vastly accelerate project timelines to get precise, accurate results to make critical decisions.
Benji Schwartz from Rocky Mountain National Lab, NIH/NIAID talks about the clinical benefits of remdesevir in rhesus macaques infected with SARS-CoV-2 virus: Listen now
Echo MS System – Ultra-high throughput quantitative mass spectrometry system delivering speed, scale and reproducibility with unyielding data quality Learn more
Pushing the boundaries of your quantitative bioanalytical studies Read ebook
Robust methods for accurate quantification in biological matrices at every stage of the process Read ebook
A new password has been sent to your email.
You have added a user.
Unfortunately the serial number you provided shows as inactive in our database. Would you like to submit the case anyway?
This serial number could not be found. Would you like to submit the case anyway?
Your password has been updated.
Your account is now created.
A verification link has been sent to your email.
A new password has been sent to your email.
Your insturment has been removed.
Your privacy settings are now updated.
Unfortunately the serial number you provided shows as inactive in our database. Please open a support case here if you require more assistance.
Software has already been registered to another instrument. Please check your AID and try again.
If you want to change the License Key to another instrument, please submit a new case.
Software has already been registered to the instrument selected.
Please check your instrument's software by going to the Instruments page and selecting the instrument in your "My Instruments" section. Here you will see a Software tab where you can view your instrument's software information.
You can also go to the Registered Software page to view software associated with your instrument(s).
If you are not finding what you are looking for, please submit a new case.